News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
140,170 Results
Type
Article (5511)
Company Profile (7)
Press Release (134652)
Multimedia
Podcasts (13)
Webinars (4)
Section
Business (53148)
Career Advice (140)
Deals (14322)
Drug Delivery (22)
Drug Development (11887)
Employer Resources (21)
FDA (1466)
Job Trends (2691)
News (77957)
Policy (3672)
Tag
Academia (214)
Accelerated approval (1)
Allergies (13)
Alliances (7216)
ALS (14)
Alzheimer's disease (177)
Antibody-drug conjugate (ADC) (28)
Approvals (1460)
Artificial intelligence (62)
Autoimmune disease (7)
Automation (1)
Bankruptcy (134)
Best Places to Work (1987)
BIOSECURE Act (3)
Biosimilars (13)
Biotechnology (12)
Bladder cancer (11)
Brain cancer (7)
Breast cancer (32)
Cancer (428)
Cardiovascular disease (44)
Career advice (123)
Career pathing (3)
CAR-T (37)
Cell therapy (113)
Cervical cancer (4)
Clinical research (10035)
Collaboration (137)
Compensation (49)
Complete response letters (2)
COVID-19 (250)
CRISPR (7)
C-suite (89)
Cystic fibrosis (17)
Data (499)
Denatured (9)
Depression (8)
Diabetes (65)
Diagnostics (1324)
Digital health (5)
Diversity (1)
Diversity, equity & inclusion (7)
Drug discovery (24)
Drug pricing (23)
Drug shortages (7)
Duchenne muscular dystrophy (21)
Earnings (30358)
Editorial (19)
Employer branding (5)
Employer resources (19)
Events (16041)
Executive appointments (276)
FDA (1694)
Frontotemporal dementia (2)
Funding (479)
Gene editing (28)
Generative AI (6)
Gene therapy (95)
GLP-1 (168)
Government (296)
Guidances (30)
Healthcare (3668)
Huntington's disease (5)
IgA nephropathy (7)
Immunology and inflammation (39)
Indications (2)
Infectious disease (279)
Inflammatory bowel disease (22)
Inflation Reduction Act (5)
Influenza (9)
Intellectual property (35)
Interviews (16)
IPO (8634)
IRA (12)
Job creations (740)
Job search strategy (115)
Kidney cancer (3)
Labor market (6)
Layoffs (95)
Leadership (2)
Legal (727)
Liver cancer (14)
Lung cancer (57)
Lymphoma (29)
Machine learning (1)
Management (5)
Manufacturing (97)
MASH (33)
Medical device (3375)
Medtech (3375)
Mergers & acquisitions (6063)
Metabolic disorders (206)
Multiple sclerosis (9)
NASH (7)
Neurodegenerative disease (22)
Neuropsychiatric disorders (8)
Neuroscience (274)
NextGen: Class of 2025 (1457)
Non-profit (328)
Now hiring (1)
Obesity (111)
Opinion (55)
Ovarian cancer (9)
Pain (20)
Pancreatic cancer (24)
Parkinson's disease (20)
Partnered (4)
Patents (60)
Patient recruitment (32)
Peanut (8)
People (13453)
Pharmaceutical (5)
Pharmacy benefit managers (2)
Phase I (3220)
Phase II (4818)
Phase III (3022)
Pipeline (689)
Policy (37)
Postmarket research (155)
Preclinical (1356)
Press Release (8)
Prostate cancer (24)
Psychedelics (4)
Radiopharmaceuticals (77)
Rare diseases (79)
Real estate (999)
Recruiting (8)
Regulatory (2940)
Reports (5)
Research institute (220)
Resumes & cover letters (21)
RNA editing (1)
RSV (5)
Schizophrenia (21)
Series A (101)
Series B (67)
Service/supplier (1)
Sickle cell disease (12)
Special edition (2)
Spinal muscular atrophy (2)
Sponsored (4)
Startups (2081)
State (1)
Stomach cancer (1)
Supply chain (15)
Tariffs (16)
The Weekly (4)
Vaccines (76)
Venture capitalists (39)
Weight loss (79)
Women's health (9)
Worklife (1)
Date
Today (56)
Last 7 days (222)
Last 30 days (708)
Last 365 days (9740)
2025 (3131)
2024 (10367)
2023 (11471)
2022 (12205)
2021 (13535)
2020 (12339)
2019 (9238)
2018 (6763)
2017 (7248)
2016 (5554)
2015 (7518)
2014 (5445)
2013 (3789)
2012 (4072)
2011 (4493)
2010 (4140)
Location
Africa (109)
Alabama (10)
Alaska (2)
Arizona (39)
Arkansas (2)
Asia (8542)
Australia (1400)
California (1827)
Canada (781)
China (86)
Colorado (94)
Connecticut (116)
Delaware (22)
Europe (17158)
Florida (285)
Georgia (56)
Idaho (10)
Illinois (95)
India (7)
Indiana (71)
Iowa (2)
Japan (22)
Kansas (25)
Kentucky (1)
Louisiana (6)
Maine (19)
Maryland (168)
Massachusetts (1152)
Michigan (118)
Minnesota (113)
Mississippi (1)
Missouri (16)
Montana (4)
Nebraska (3)
Nevada (28)
New Hampshire (19)
New Jersey (459)
New Mexico (5)
New York (595)
North Carolina (282)
North Dakota (1)
Northern California (744)
Ohio (37)
Oklahoma (4)
Oregon (4)
Pennsylvania (457)
Puerto Rico (2)
Rhode Island (8)
South America (202)
South Carolina (3)
Southern California (758)
Tennessee (14)
Texas (330)
United States (6592)
Utah (43)
Virginia (68)
Washington D.C. (9)
Washington State (180)
West Virginia (2)
Wisconsin (6)
140,170 Results for "sequoia capital".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
OpenEvidence Achieves $1 Billion Valuation in Sequoia-led Round and Announces Content Partnership with the New England Journal of Medicine
February 19, 2025
·
4 min read
Biotech Bay
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
BeiGene, Ltd., a global oncology company, announced the presentation of new data from the SEQUOIA study of BRUKINSA® at the European Hematology Association 2024 Hybrid Congress in Madrid, Spain in an oral session.
June 14, 2024
·
14 min read
Biotech Bay
Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress
Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress.
May 13, 2024
·
15 min read
Drug Development
Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress
Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress.
May 13, 2024
·
13 min read
News
Cytokinetics Presents Additional Data from SEQUOIA-HCM at the HCMS Scientific Sessions
September 27, 2024
·
9 min read
Press Releases
Cytokinetics Presents Additional Data From SEQUOIA-HCM at the HFSA Annual Scientific Meeting
September 30, 2024
·
9 min read
Biotech Bay
Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
Cytokinetics, Incorporated announced it will host an investor event and conference call on May 13, 2024 at 4:00 PM Western European Summer Time to discuss the primary results from SEQUOIA-HCM, which are being presented in a Late Breaking Clinical Trial session at Heart Failure 2024, an International Congress of the European Society of Cardiology.
April 29, 2024
·
4 min read
Biotech Bay
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
Cytokinetics, Incorporated today announced three Late Breaking Clinical Trial presentations relating to SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), at Heart Failure 2024, an International Congress of the European Society of Cardiology, taking place in Lisbon, Portugal from May 11, 2024 – May 14, 2024.
April 10, 2024
·
5 min read
Press Releases
Cytokinetics Presents Additional Data From SEQUOIA-HCM at the European Society of Cardiology Congress 2024
September 2, 2024
·
17 min read
Mergers & acquisitions
Acelyrin Adopts Poison Pill to Ward Off Tang Capital Buy
The move by Acelyrin’s board comes as the venture capital firm has taken larger and larger stakes in the company in an attempt to disrupt a merger with Alumis.
March 13, 2025
·
1 min read
·
Dan Samorodnitsky
1 of 14,017
Next
